

32. The method of claim 28 wherein said joint is selected from the group consisting of knee joints, and the temporal mandibular joint.

33. The method of Claim 28 wherein said mesenchymal stem cells are autologous to the recipient.

34. The method of Claim 28 wherein said mesenchymal stem cells are allogeneic to the recipient.

35. A method of repairing meniscal damage in a joint, comprising:
injecting into said joint a liquid suspension comprising mesenchymal stem cells and an acceptable pharmaceutical carrier, whereby said mesenchymal stem cells differentiate into meniscal tissue, said mesenchymal stem cells being injected in an amount effective to repair said meniscal damage in said joint.

36. The method of Claim 35 wherein said pharmaceutical carrier comprises hyaluronan or a salt thereof.

37. The method of Claim 36 wherein said hyaluronan or salt thereof is sodium hyaluronate.

38. The method of Claim 35 wherein said injection is into the joint space of said joint.

39. The method of claim 35 wherein said joint is selected from the group consisting of knee joints, and the temporal mandibular joint.

40. The method of Claim 35 wherein said mesenchymal stem cells are autologous to the recipient.

41. The method of Claim 35 wherein said mesenchymal stem cells are allogeneic to the recipient.

42. A method of preventing or reducing subchondral bone sclerosis in a joint, comprising:

injecting into said joint a liquid suspension comprising mesenchymal stem cells and an acceptable pharmaceutical carrier, whereby said mesenchymal stem cells differentiate into meniscal tissue.

43. The method of Claim 42 wherein said pharmaceutical carrier comprises hyaluronan or a salt thereof.

44. The method of Claim 43 wherein said hyaluronan or salt thereof is sodium hyaluronate.

45. The method of Claim 42 wherein said injection is into the joint space of said joint.

46. The method of Claim 42 wherein said joint is selected from the group consisting of knee joints, and the temporal mandibular joint.

47. The method of Claim 42 wherein said mesenchymal stem cells are autologous to the recipient.

48. The method of Claim 42 wherein said mesenchymal stem cells are allogeneic to the recipient.

49. A method of preventing or reducing the formation of osteophytes in a joint, comprising:

injecting into said joint a liquid suspension comprising mesenchymal stem cells and an acceptable pharmaceutical carrier, whereby said mesenchymal stem cells differentiate into meniscal tissue.

50. The method of Claim 49 wherein said pharmaceutical carrier comprises hyaluronan or a salt thereof.

51. The method of Claim 50 wherein said hyaluronan or salt thereof is sodium hyaluronate.

52. The method of Claim 49 wherein said injection is into the joint space of said joint.

53. The method of claim 49 wherein said joint is selected from the group consisting of knee joints, and the temporal mandibular joint.

54. The method of Claim 49 wherein said mesenchymal stem cells are autologous to the recipient.

55. The method of Claim 49 wherein said mesenchymal stem cells are allogeneic to the recipient.

56. A method of protecting cartilage in a joint of an animal, comprising:
injecting into said joint a liquid suspension comprising mesenchymal stem cells and an acceptable pharmaceutical carrier, whereby said mesenchymal stem cells differentiate into meniscal tissue adjacent said cartilage.

57. The method of Claim 56 wherein said pharmaceutical carrier comprises hyaluronan or a salt thereof.

58. The method of Claim 57 wherein said hyaluronan or salt thereof is sodium hyaluronate.

59. The method of Claim 56 wherein said injection is into the joint space of said joint.

60. The method of Claim 56 wherein said joint is selected from the group consisting of knee joints and the temporal mandibular joint.

61. The method of Claim 56 wherein said mesenchymal stem cells are autologous to the recipient.

62. The method of Claim 56 wherein said mesenchymal stem cells are allogeneic to the recipient.

REMARKS

Reconsideration of the above-identified application is hereby respectfully requested.

Claims 1-27 have been canceled without prejudice and Claims 28-62 have been added.

The fact that Claims 1-27 have been canceled without prejudice is not to be construed as an